Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.

Pharmacogenetics and genomics - 1 Jul 2008

Kohlrausch Fabiana B, Gama Clarissa S, Lobato Maria Inês, Belmonte-de-Abreu Paulo, Callegari-Jacques Sidia M, Gesteira Alejandro, Barros Francisco, Carracedo Angel, Hutz Mara H

Abstract excerpt

OBJECTIVES: This study aimed to explore the influence of variation in DRD2, DRD3, CYP2D6, CYP3A4, and CYP3A5 genes on treatment resistance to typical neuroleptics in a Brazilian sample of patients with schizophrenia. METHODS: One polymorphism at DRD2 gene, five at DRD3, 24 at CYP2D6, nine at CYP3A4 gene, and one at CYP3A5 gene were genotyped in a sample of 186 patients with schizophrenia. RESULTS: From the nine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme System

Share to Drug Resistance

Share to Pharmacogenetics

Share to Receptors, Dopamine D2

Share to Receptors, Dopamine D3

Source

Identifiers

PMID: 18551040
DOI: 10.1097/FPC.0b013e328301a763

Genes

DRD3
DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.PMID 18551040Read ↗

Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophreniaSemantic proximity Read ↗

DRD2, DRD3, and HTR2A Single-Nucleotide Polymorphisms Involvement in High Treatment Resistance to Atypical Antipsychotic DrugsSemantic proximity Read ↗

Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness.Semantic proximity Read ↗

Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia.Semantic proximity Read ↗

Investigating DRD2 and HTR2A polymorphisms in treatment-resistant schizophrenia: a comparative analysis with other treatment-resistant mental disorders and the healthy state.Semantic proximity Read ↗

DRD1 rs4532 polymorphism: a potential pharmacogenomic marker for treatment response to antipsychotic drugs.Semantic proximity Read ↗

ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting.Semantic proximity Read ↗

Frequency of "Poor Transporter" Phenotype Among Patients with Mental Disorders: Pilot StudySemantic proximity Read ↗

DRD3 Ser9Gly polymorphism and treatment response to antipsychotics in schizophrenia: A meta-analysis.Semantic proximity Read ↗

Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia.Semantic proximity Read ↗

Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.Semantic proximity Read ↗

Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.